Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

LIVE: FTSE 100 dips, AstraZeneca surges, house prices higher in February

Currys takeover bid rejected Moneysupermarket nets strong insurance earnings FTSE 100 opens lower, AstraZeneca surges 9.16am: House prices see first…

FTSE 100 LIVE: Index climbs as Barclays, AstraZeneca gain

FTSE 100 up 13 points at 7,725. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 1.22pm: In case you missed it… easyJet founder calls…

FTSE 100 LIVE: AstraZeneca, Rolls-Royce climb; Ex-BoE chief warns on economy

FTSE 100 up 10 points at 7,722. Currys centre of bidding war. AstraZeneca, Rolls-Royce surge. 11.33am: AstraZeneca, Rolls-Royce lead risers AstraZeneca led...…

FTSE 100 LIVE: Index approaches six-month high

FTSE 100 up 21 points at 7,732. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 3.30pm: YouGov chief departs in key election year YouGov...…

Tagrisso plus chemo approved in US for lung cancer

19 February 2024 Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer Approval based on FLAURA2…

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell…

Tagrisso improved PFS in Stage III lung cancer

19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First…

AstraZeneca: Kurszielsenkung

Toronto (www.aktiencheck.de) - Rating-Update: BMO Capital Markets stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London Stock…

Goldman Sachs Says ‘GRANOLAS’ Set to Enjoy Further Gains

Large-cap European firms with a global footprint and strong balance sheets have outperformed the ‘Magnificent Seven’ US stocks and are…

AstraZeneca unter der Lupe

Anzeige / WerbungAstraZeneca unter der LupeAstraZeneca ist einer der größten Arzneimittelhersteller weltweit. Ein international renommierter Pharmakonzern, der in 1999 aus…

AstraZeneca unter der Lupe

…

AstraZeneca downgraded as analysts highlight ‘underwhelming’ year end

AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a…

FTSE 100 drops, Dow remains bid and Nikkei 225 makes new 34-year high

Major Indices Update: FTSE 100 drops on AstraZeneca disappointment Dow trades close to record highs Nikkei 225 scales new 34-year…

FDA grants Fast Track to Ionis and AstraZenecas ATTR-CM treatment By Investing.com

FDA grants Fast Track to Ionis and AstraZenecas ATTR-CM treatment…

Pharma Stock Roundup: AZN & LLYs Q4 Earnings, NVO, NVS & MRKs M&A Deals

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.…

Ionis (IONS) Eplontersen Gets Fast Track Tag for New Indication

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZenecas (AZN) eplontersen for treating adults with transthyretin-mediated…

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

AZN earnings call for the period ending December 31, 2023.…

AstraZeneca CEO Says China Has Become Fundamental Part of Pharma Industry

After AstraZeneca reported lower-than-expected profit, CEO Pascal Soriot spoke with Bloombergs Anna Edwards, Kriti Gupta and Guy Johnson. (Source: Bloomberg)…

AstraZeneca PLC 2023 Q4 - Results - Earnings Call Presentation

…

AstraZeneca CEO Says Market Access Is Turning Pharma Off the UK

Hurdles in bringing drugs to market in the UK is putting pharmaceutical companies off investing, said the chief executive officer…

AstraZenecas earnings top estimates but shares fall on core operating profit drop By Investing.com

AstraZenecas earnings top estimates but shares fall on core operating profit drop…

Astrazeneca says Catalent deal shows importance of in-house capacity By Reuters

Astrazeneca says Catalent deal shows importance of in-house capacity…

AstraZeneca core earnings lagged estimates

…

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low…

AstraZeneca, Compass, SSE and BAT: Day ahead on Thursday

Having lost its number one spot on the FTSE 100 last year, AstraZeneca PLC (LSE:AZN) boss Pascal Soriot will no doubt be…

AstraZeneca invests $300 million in Maryland facility By Investing.com

AstraZeneca invests $300 million in Maryland facility…

AstraZeneca facing three big investor debates as results loom, says Barclays

AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three...…

Zentalis: Leading WEE1 Developer After AstraZenecas Exit

…

AstraZeneca (AZN) to Report Q4 Earnings: Heres What to Expect

Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…

AstraZenecas Q4 Earnings: Recognizing The Underrated Gems Growth

…

AstraZenecas mini acquisition spree comes as core oncology drugs face pressure

AstraZeneca PLC (LSE:AZN) recently committed to reporting how its business impacts nature as part of annual corporate results, but next…

Total Voting Rights

1 February 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

AstraZenecas (AZN) sBLA for Enhertu Gets FDAs Priority Tag

AstraZenecas (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final…

AstraZeneca: Ersteinschätzung

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol:…

Hepatocellular Carcinoma Drugs (PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors) Industry Report 2024: A $1.62 Billion Market Opportunity by 2028

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Hepatocellular Carcinoma Drugs Global Market Report 2024" report has been…

dpa-AFX ProFeed